AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PST). The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will discuss the company's Q2 2025 financial and business results.
The webinar will include a Q&A session, with participants able to submit questions through the registration page. A replay will be made available on AVITA Medical's investor relations website after the event.
AVITA Medical (NASDAQ: RCEL) ha annunciato un webinar per gli investitori previsto per 14 agosto 2025 alle 9:00 AEDT (13 agosto alle 16:00 PST). La presentazione vedr脿 la partecipazione del CEO Jim Corbett e del CFO David O'Toole, che illustreranno i risultati finanziari e operativi del secondo trimestre 2025.
Il webinar comprender脿 una sessione di domande e risposte; i partecipanti potranno inviare le domande tramite la pagina di registrazione. Dopo l'evento sar脿 disponibile una registrazione nella sezione investor relations del sito di AVITA Medical.
AVITA Medical (NASDAQ: RCEL) ha anunciado un seminario web para inversores programado para el 14 de agosto de 2025 a las 9:00 AEDT (13 de agosto a las 16:00 PST). La presentaci贸n contar谩 con el CEO Jim Corbett y el CFO David O'Toole, quienes hablar谩n sobre los resultados financieros y operativos del segundo trimestre de 2025.
El webinar incluir谩 una sesi贸n de preguntas y respuestas; los participantes podr谩n enviar preguntas a trav茅s de la p谩gina de registro. Tras el evento, se publicar谩 una grabaci贸n en la web de relaciones con inversores de AVITA Medical.
AVITA Medical (NASDAQ: RCEL)鞚赌(电�) 2025雲� 8鞗� 14鞚� 鞓れ爠 9鞁� AEDT(8鞗� 13鞚� 鞓ろ泟 4鞁� PST)鞐� 鞓堨爼霅� 韴瀽鞛� 鞗箘雮橂ゼ 氚滍憸頄堨姷雼堧嫟. 氚滍憸鞐愲姅 CEO 歆� 旖旊渤(Jim Corbett)瓿� CFO 雿办澊牍勲摐 鞓ろ埓(David O'Toole)鞚� 彀胳棳頃橃棳 2025雲� 2攵勱赴 鞛 氚� 靷梾 靹标臣毳� 靹る獏頃� 鞓堨爼鞛呺媹雼�.
鞗箘雮橃棎電� 歆堨潣鞚戨嫷 鞁滉皠鞚� 韽暔霅橂┌, 彀戈皜鞛愲姅 霌彪 韼橃澊歆�毳� 韱淀暣 歆堧鞚� 鞝滌稖頃� 靾� 鞛堨姷雼堧嫟. 頄夓偓 頉� AVITA Medical鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐� 雲鬼檾臧� 瓴岇嫓霅� 鞓堨爼鞛呺媹雼�.
AVITA Medical (NASDAQ: RCEL) a annonc茅 un webinaire destin茅 aux investisseurs pr茅vu le 14 ao没t 2025 脿 9h AEDT (13 ao没t 脿 16h PST). La pr茅sentation sera anim茅e par le PDG Jim Corbett et le directeur financier David O'Toole, qui pr茅senteront les r茅sultats financiers et op茅rationnels du deuxi猫me trimestre 2025.
Le webinaire comprendra une s茅ance de questions-r茅ponses ; les participants pourront soumettre leurs questions via la page d'inscription. Un enregistrement sera mis en ligne sur le site des relations investisseurs d'AVITA Medical apr猫s l'茅v茅nement.
AVITA Medical (NASDAQ: RCEL) hat ein f眉r 14. August 2025 um 9:00 AEDT (13. August um 16:00 PST) angek眉ndigtes Investoren-Webinar bekanntgegeben. In der Pr盲sentation werden CEO Jim Corbett und CFO David O'Toole die finanziellen und gesch盲ftlichen Ergebnisse des zweiten Quartals 2025 erl盲utern.
Das Webinar umfasst eine Fragerunde; Teilnehmer k枚nnen Fragen 眉ber die Registrierungsseite einreichen. Eine Aufzeichnung wird nach der Veranstaltung auf der Investor-Relations-Website von AVITA Medical verf眉gbar sein.
- None.
- None.
VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O鈥橳oole, Chief Financial Officer, on August 14, 2025, at 9 AM Australian Eastern Daylight Time (August 13 at 4 PM U.S. Pacific Standard Time).
The webinar presentation will cover financial and business results from our recent second-quarter 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
Register:
A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical庐 is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL庐 System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient鈥檚 own skin to create Spray-On Skin鈩� Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm庐, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx鈩�, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burns and trauma wounds. The RECELL System, excluding RECELL GO庐, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit聽.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is AVITA Medical's (RCEL) Q2 2025 investor webinar?
Who will present at AVITA Medical's investor webinar?
How can investors participate in AVITA Medical's Q2 2025 webinar?
Where can I watch the replay of AVITA Medical's investor presentation?
